Skip to main content
Erschienen in: Diabetologia 3/2006

01.03.2006 | Short Communication

Increased risk of obesity associated with the variant allele of the PPARGC1A Gly482Ser polymorphism in physically inactive elderly men

verfasst von: M. Ridderstråle, L. E. Johansson, L. Rastam, U. Lindblad

Erschienen in: Diabetologia | Ausgabe 3/2006

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

The variant allele of the Gly482Ser polymorphism in peroxisome proliferator-activated receptor-γ co-activator-1α (PPARGC1A or PGC1α), a critical determinant of skeletal muscle metabolism, has been associated with obesity and type 2 diabetes. Previous studies indicate that these risks depend on sex and environmental triggers such as age. The aim of the present study was to investigate the possible interactions between genotype and age and physical activity on risk of obesity.

Methods

We genotyped PPARGC1A Gly482Ser, in a population-based study comprising 899 women and 902 men aged between 30 and 75 years in Vara, Sweden.

Results

Genotyping revealed that 56% of the males and 57% of the females carried the PPARGC1A 482Ser variant allele. Elderly males (≥50 years) carrying 482Ser had an increased risk of obesity compared with subjects who were homozygous for the wild-type allele (odds ratio [OR]=1.99, 95% CI 1.14–3.47, p=0.015). The risk was restricted to males with a low leisure-time physical activity level, and was significantly weaker (OR=0.44, 95% CI 0.22–0.87, p=0.018) for the homozygous 482Gly carriers among this subgroup. No association with obesity was found in elderly males with a high level of physical activity, in younger males, or in females of any age group or level of physical activity.

Conclusions/interpretation

Our findings confirm that sex and age should be considered when investigating the influence of the PPARGC1A Gly482Ser polymorphism on metabolic disease. The risk of obesity associated with 482Ser is evident only in physically inactive elderly male subjects. Whenever possible, the level of physical activity should be addressed in future studies on disease risk associated with PPARGC1A Gly482Ser.
Literatur
1.
Zurück zum Zitat McCarty MF (2005) Up-regulation of PPARγ coactivator-1α as strategy for preventing and revering insulin resistance and obesity. Med Hypotheses 64:399–407CrossRefPubMed McCarty MF (2005) Up-regulation of PPARγ coactivator-1α as strategy for preventing and revering insulin resistance and obesity. Med Hypotheses 64:399–407CrossRefPubMed
2.
Zurück zum Zitat Mootha VK, Lindgren CM, Eriksson KF et al (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34:267–273CrossRefPubMed Mootha VK, Lindgren CM, Eriksson KF et al (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34:267–273CrossRefPubMed
3.
Zurück zum Zitat Patti ME, Butte AJ, Crunkhorn S et al (2003) Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci U S A 100:8466–8471CrossRefPubMed Patti ME, Butte AJ, Crunkhorn S et al (2003) Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci U S A 100:8466–8471CrossRefPubMed
4.
Zurück zum Zitat Stone S, Abkevich V, Hunt SC et al (2002) A major predisposition locus for severe obesity, at 4p15–p14. Am J Hum Genet 70:1459–1468CrossRefPubMed Stone S, Abkevich V, Hunt SC et al (2002) A major predisposition locus for severe obesity, at 4p15–p14. Am J Hum Genet 70:1459–1468CrossRefPubMed
5.
Zurück zum Zitat Ek J, Andersen G, Urhammer SA et al (2001) Mutation analysis of peroxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to Type II diabetes mellitus. Diabetologia 44:2220–2226CrossRefPubMed Ek J, Andersen G, Urhammer SA et al (2001) Mutation analysis of peroxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to Type II diabetes mellitus. Diabetologia 44:2220–2226CrossRefPubMed
6.
Zurück zum Zitat Hara K, Tobe K, Okada T et al (2002) A genetic variation in the PGC-1 gene could confer insulin resistance and susceptibility to Type II diabetes. Diabetologia 45:740–743CrossRefPubMed Hara K, Tobe K, Okada T et al (2002) A genetic variation in the PGC-1 gene could confer insulin resistance and susceptibility to Type II diabetes. Diabetologia 45:740–743CrossRefPubMed
7.
Zurück zum Zitat Esterbauer H, Oberkofler H, Linnemayer V et al (2002) Peroxisome proliferator-activated receptor-γ coactivator-1 gene locus. Association with obesity indices in middle-aged women. Diabetes 51:1281–1286PubMedCrossRef Esterbauer H, Oberkofler H, Linnemayer V et al (2002) Peroxisome proliferator-activated receptor-γ coactivator-1 gene locus. Association with obesity indices in middle-aged women. Diabetes 51:1281–1286PubMedCrossRef
8.
Zurück zum Zitat Ling C, Poulsen P, Carlsson E et al (2004) Multiple environmental and genetic factors influence skeletal muscle PGC-1α and PGC-1β gene expression in twins. J Clin Invest 114:1518–1526CrossRefPubMed Ling C, Poulsen P, Carlsson E et al (2004) Multiple environmental and genetic factors influence skeletal muscle PGC-1α and PGC-1β gene expression in twins. J Clin Invest 114:1518–1526CrossRefPubMed
9.
Zurück zum Zitat Bøg-Hansen E, Merlo J, Gullberg B, Melander A, Rastam L, Lindblad U (2004) Survival in patients with hypertension treated in primary care. A population-based follow-up study in the Skaraborg Hypertension and Diabetes Project. Scand J Prim Health Care 22:222–227CrossRefPubMed Bøg-Hansen E, Merlo J, Gullberg B, Melander A, Rastam L, Lindblad U (2004) Survival in patients with hypertension treated in primary care. A population-based follow-up study in the Skaraborg Hypertension and Diabetes Project. Scand J Prim Health Care 22:222–227CrossRefPubMed
10.
Zurück zum Zitat Caspersen CJ, Powell KE, Christenson GM (1985) Physical activity, exercise, and physical fitness: definitions and distinctions for health-related research. Public Health Rep 100:126–131PubMed Caspersen CJ, Powell KE, Christenson GM (1985) Physical activity, exercise, and physical fitness: definitions and distinctions for health-related research. Public Health Rep 100:126–131PubMed
11.
Zurück zum Zitat Ambye L, Rasmussen S, Fenger M et al (2005) Studies of the Gly482Ser polymorphism of the peroxisome proliferator-activated receptor g coactivator 1α (PGC-1α) gene in Danish subjects with the metabolic syndrome. Diabetes Res Clin Pract 67:175–179CrossRefPubMed Ambye L, Rasmussen S, Fenger M et al (2005) Studies of the Gly482Ser polymorphism of the peroxisome proliferator-activated receptor g coactivator 1α (PGC-1α) gene in Danish subjects with the metabolic syndrome. Diabetes Res Clin Pract 67:175–179CrossRefPubMed
12.
Zurück zum Zitat Lacquemant C, Chikri M, Boutin P, Samson C, Frougel P (2002) No association between the G482S polymorphism of the proliferator-activated receptor-γ coactivator-1 (PGC-1) gene and type II diabetes in French Caucasians. Diabetologia 45:602–603CrossRefPubMed Lacquemant C, Chikri M, Boutin P, Samson C, Frougel P (2002) No association between the G482S polymorphism of the proliferator-activated receptor-γ coactivator-1 (PGC-1) gene and type II diabetes in French Caucasians. Diabetologia 45:602–603CrossRefPubMed
13.
Zurück zum Zitat Andruliontytè L, Zacharova J, Chiasson J-L, Laakso M (2004) Common polymorphisms of the PPAR-γ2 (Pro12Ala) and PGC-1α (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial. Diabetologia 47:2176–2184CrossRefPubMed Andruliontytè L, Zacharova J, Chiasson J-L, Laakso M (2004) Common polymorphisms of the PPAR-γ2 (Pro12Ala) and PGC-1α (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial. Diabetologia 47:2176–2184CrossRefPubMed
14.
Zurück zum Zitat Lin J, Wu H, Tarr PT et al (2002) Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature 418:797–801CrossRefPubMed Lin J, Wu H, Tarr PT et al (2002) Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature 418:797–801CrossRefPubMed
15.
Zurück zum Zitat Nyholm B, Qu Z, Kaal A et al (1997) Evidence of an increased number of type IIb muscle fibers in insulin-resistant first-degree relatives of patients with NIDDM. Diabetes 46:1822–1828PubMedCrossRef Nyholm B, Qu Z, Kaal A et al (1997) Evidence of an increased number of type IIb muscle fibers in insulin-resistant first-degree relatives of patients with NIDDM. Diabetes 46:1822–1828PubMedCrossRef
Metadaten
Titel
Increased risk of obesity associated with the variant allele of the PPARGC1A Gly482Ser polymorphism in physically inactive elderly men
verfasst von
M. Ridderstråle
L. E. Johansson
L. Rastam
U. Lindblad
Publikationsdatum
01.03.2006
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 3/2006
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-005-0129-8

Weitere Artikel der Ausgabe 3/2006

Diabetologia 3/2006 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.